Table 1.
Summary of patient demographics and baseline disease characteristics, n (%)
| Variable | TACE/HAIC + S-1, n = 55 | TACE/HAIC, n = 60 | P value |
| Age in yr | 0.210 | ||
| mean ± SD (range) | 56.3 ± 10.9 (34-81) | 59.1 ± 12.7 (22-82) | |
| Sex | 0.709 | ||
| Male | 49 (89.1) | 51 (85.0) | |
| Female | 6 (10.9) | 9 (15.0) | |
| Liver disease etiology | 0.237 | ||
| HBV | 47 (85.5) | 45 (75.0) | |
| HCV | 4 (7.3) | 6 (10.0) | |
| HBV and HCV | 1 (1.8) | 0 | |
| Unknown | 3 (5.5) | 9 (15.0) | |
| Performance status | 0.756 | ||
| 0 | 40 (72.7) | 41 (68.3) | |
| 1 | 15 (27.3) | 19 (31.7) | |
| Child-Pugh stage | 0.642 | ||
| A | 47 (85.5) | 55 (91.7) | |
| B | 8 (14.5) | 5 (8.3) | |
| Tumor maximal size in cm | 0.530 | ||
| mean ± SD (range) | 9.7 ± 4.7 (2.2-25.3) | 10.2 ± 4.2 (2.5-21.0) | |
| Number of tumors | 0.683 | ||
| 1 | 16 (29.1) | 19 (31.7) | |
| ≥ 2 | 34 (61.8) | 38 (63.3) | |
| Infiltrative | 5 (9.1) | 3 (5.0) | |
| Portal vein invasion | 0.649 | ||
| No invasion | 21 (38.2) | 18 (30.0) | |
| Stage I-II | 24 (43.6) | 30 (50.0) | |
| Stage III-IV | 10 (18.2) | 12 (20.0) | |
| Extrahepatic metastasis | 0.274 | ||
| Yes | 41 (74.5) | 38 (63.3) | |
| No | 14 (25.5) | 22 (36.7) | |
| Targeted treatment | 0.846 | ||
| Yes | 9 (16.4) | 8 (13.3) | |
| No | 46 (83.6) | 52 (86.7) | |
| AFP in ng/mL | 0.579 | ||
| Median (range) | 4833 (0.9-1974770) | 5561 (0.6-1207090) |
AFP: Alpha-fetoprotein; HAIC: Hepatic arterial infusion chemotherapy; SD: Standard deviation; HBV: Hepatitis B virus; HCV: Hepatitis C virus; TACE: Transarterial chemoembolization.